A therapeutic agent for cognitive impairment and a therapeutic agent for Alzheimer's disease induced by amyloid β protein, and a therapeutic method and a pathological condition analysis method related thereto
An object of the present invention is to provide an anti-Alzheimer agent having an amyloid β protein as a mechanism of action, but different from the conventional mechanism of action. The therapeutic agent for Alzheimer's disease according to the present invention comprises a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or a similar peptide, particularly a peptide comprising the amino acid sequence represented by SEQ ID NO: 2 which is a partial sequence of SEQ ID NO: 1. It contains a therapeutic agent for cognitive impairment induced by the amyloid β protein contained therein, and the therapeutic agent. VLSSQQFLHRGHQPPPEMAGHSLASSHRNSMIPSAAT (SEQ ID NO: 1) HRHGHQPPPEMA (SEQ ID NO: 2)本発明は、アミロイドβ蛋白質を作用機序とするが、従来の作用機序とは異なる抗アルツハイマー剤を提供することを課題とする。本発明に係るアルツハイマー病治療薬は、配列番号１で表されるアミノ酸配列からなるペプチドまたはこれに類するペプチド、特に配列番号１の部分配列である配列番号２で表されるアミノ酸配列を含むペプチドを含有するアミロイドβ蛋白質により誘発される認知障害の治療剤、および当該治療剤を含有することを特徴とする。ＶＬＳＳＱＱＦＬＨＲＧＨＱＰＰＰＥＭＡＧＨＳＬＡＳＳＨＲＮＳＭＩＰＳＡＡＴ （配列番号１）ＨＲＧＨＱＰＰＰＥＭＡ （配列番号２）
